Form 4: Arcus Biosciences Chief Accounting Officer Sells Shares Under 10b5-1 Plan

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 201 shares of common stock at $15.32 per share, according to a recent SEC filing.

Summary

• Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, sold 201 shares of common stock on December 2, 2024, at a price of $15.32 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• The filing also notes that Mr. Azoy acquired 201 shares on November 29, 2024, through the company's Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment.

Risks

• Sales by company officers can sometimes be perceived negatively by the market, although this sale was pre-planned under a 10b5-1 trading plan.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any new material non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
• The volume of shares sold is relatively small, suggesting this is not a major divestment by the officer.

Stakeholder Impact

• The sale of shares by a company officer may have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates this.

Key Dates

Keywords

Arcus Biosciences, SEC Form 4, insider trading, Rule 10b5-1, stock sale, Alexander Azoy, Chief Accounting Officer, employee stock purchase plan